Supervisory board

  1. Supervisory Board

Prof. Joachim Schindler, PhD

Chairman of the Supervisory Board

After studying Business Administration (incl. a PhD), Joachim worked with accounting firms, has been with KPMG since 1989. He is a Chartered Accountant and a Tax Adviser. Joachim’s experience ranges from servicing medium size to very large clients in Audit...

... Tax and Advisory. For more than 20 years, his focus has been on multinational companies and how to service them in the best possible way. During this time he spent three years in London. Joachim served in a number of key leadership positions. In addition to serving as Head of Audit and a Member of the Managing Board for KPMG Germany from 2004 to 2012, Joachim was Head of Audit for the Europe, Middle East and Africa region from 2005 to 2010 and Global Head of Audit and a Member of the Global Executive Team from 2010 to 2013.

He also serves on the board of a non-profit hospital group. In 2013 he additionally started to advise this group in finance and strategic matters in a fairly comprehensive way.

Joachim regularly lectures on accounting and auditing and he has published several articles in professional journals. He is an Honorary Professor at the Freie Universität Berlin. He serves currently as Vice-Chairman on the board of the IDW, the German Institute of Chartered Accountants.

Christoph Ehlers, LLM

Member of the Supervisory Board

Christoph Ehlers is a German lawyer who obtained his degrees from the University of Konstanz, Germany, and the University of San Diego, CA. From 1983 to 1997, he held different positions at Commerzbank AG, Germany’s second largest private bank, e.g. in investment ...

... banking and as executive assistant to the CEO. From 1992 to 1997, he was responsible for the management of all branches in Southwestern Germany. Since 1997, he started his own businesses, working i.a. as a business angel concentrating on developing technology driven companies, especially in Life Science. Under his leadership numerous German companies thrived to success. Apart from his involvement in the technological sector, Christoph Ehlers is owner of Equicore Beteiligungs GmbH, founder and substantial shareholder of the Freiburger Vermögensmanagement GmbH (one of the leading private German portfolio management companies). He is also the co-founder and Board member of one of the leading German economic and political think tanks, the "Stiftung Ordnungspolitik – Centrum für Europäische Politik", located in Freiburg. In addition, he is a member of various consulting boards.

Christoph is one of the major and initial shareholders of CENTOGENE since 2008. In the initial years he served the company as Managing Director.

Since June 1, 2014, he is a member of CENTOGENE’s Supervisory Board focusing on the strategic orientation and development of the company.

Prof. Mathias Freund, MD

Member of the Supervisory Board

Chairman of the Department of Hematology and Oncology at Rostock University. Secretary and Treasurer of the German Society of Hematology and Oncology since 1996. Chairman of the Tumor Center of Rostock and Member in numerous scientific societies.

Published 291 journal articles, 24 books, 88 book chapters and 678 abstracts.

He graduated in medicine at the Eberhard-Karls-University in Tübingen, Germany in 1974, obtained his physician's license, doctorate and his license as a specialist of Internal Medicine and Hematology/Oncology at the same institution. His research activities in Tübingen focused on disseminated intravascular coagulation and shock lung, breast cancer, leukemias and non-Hodgkin's lymphomas. In 1982, he moved to the Department of Hematology and Oncology at Hannover Medical School. His clinical activities concentrated on high-grade and low-grade malignant non-Hodgkin's lymphomas as well as chronic and acute leukemias. Besides chemotherapeutic approaches, he also developed a special interest in the basic and clinical effects of cytokines. Prof. Freund subsequently chaired the Laboratory of Experimental Hematology. His activities focused on cell biologic aspects of growth and differentiation of acute and chronic leukemias as well as stem cell biology. Clinical and basic developments were documented in a series of International Symposia on Cytokines in Hematology, Oncology and Immunology in Hannover in 1989, 1991, and 1993. Prof. Freund was secretary of the annual meeting of the German Society of Hematology and Oncology in Hannover 1989. In 1989, he received the ESMO European Certificate in Medical Oncology. In October 1994, Prof. Freund was appointed as chairman of the Department of Hematology and Oncology at Rostock University. His research concentrates on high-dose chemotherapy of hematopoietic neoplasias and solid tumors, bone marrow and blood stem cell transplantation and chronic GvHD. Recently, the department is involved in stem cell therapy for myocardial and vascular regeneration. Prof. Freund has been licensed as a specialist in Hemostaseology and in Palliative Medicine in 2008.

The following business companies have been established in the surrounding of the Department of Hematology and Oncology which is chaired by Prof. Freund:

  • M.D. Medical Development GmbH, Rostock
  • Seracell Stammzelltechnologie GmbH (former Gesellschaft für Stammzelltechnologie Rostock GmbH)
  • Seracell Pharma AG Medical Development in Immunology GmbH, Rostock
  • Institut für Integrative Medizin an der Universität Rostock gGmbH i.G.

Prof. Freund holds equities in these companies directly and indirectly.

Prof. Freund was President of the Annual Meeting of the German, Austrian and Swiss Societies of Hematology and Oncology in 2005. Also, since 1996 he is President of the Cancer Society of Mecklenburg-Vorpommern.

He is Chairman of the Supervisory Board of the Seracell AG.

Holger Friedrich

Member of the Supervisory Board

Holger Friedrich has more than 25 years of experience in the IT industry. His focus is on software engineering and IT architecture management. Holger holds several leadership positions in leading institutions, among others as partner of a global management ...

...consulting firm or as an executive board member in several technology firms. Amongst other positions, he served as chairman of SPM Technologies (acquired by SAP), was Partner at McKinsey and Board member at Software AG. Besides that, Holger was an executive board member of CORE, a think tank for technologies in the financial services industry.

Jacob Kaluski, M.Sc. in Pharmacy

Member of the Supervisory Board

Jacob Kaluski has more than 30 years of experience from the pharmaceutical industry focusing on international marketing and drug development/clinical trials. He has held several leadership positions within Pharmacia, among others as Vice President and Business Manager for growth hormone.

Amongst other positions, he served as chairman of DuoCort AB, Bioimics AB and Jederstrom Pharmaceuticals. Besides that, Jacob was a board member of Glactone Pharma AB and Pulsetten AB. Jacob Kaluski is a co-founder of TKT-Europe-5S, which launched the first orphan drug in Europe.

Michael Schlenk, MBA

Member of the Supervisory Board

Michael Schlenk earned a Diplom-Kaufmann degree from University Hamburg, Germany, and an MBA from University Bradford Management Centre, United Kingdom. After 6 years as a management consultant in the area of technology transfer, Michael Schlenk worked more than 20 years in the Life Science industry.

During his international career, he worked and lived in more than 10 countries. He held positions as strategic consultant, marketing manager, area manager, general manager and president of subsidaries of Novartis and Abbott. Before joining CENTOGENE, Michael was CEO of Berlin based Biotechnology company ProBioGen AG for 7 years. He led the company to sustained profitability and prepared it for the trade sale. Under his leadership, the organisation achieved numerous awards for fast growth and technological excellence: Deloitte Fast Forward Award (2 times), Step Award (FAZ German newspaper), BMBF and Peta. In 2010, ProBioGen AG was sold successfully to a leading Egyptian Pharma company.

Since 2003, Michael develops and invests as a business angel in young IT and Life Science companies. He is a member of various supervisory boards. In January 2011, Michael has invested, became shareholder and was designated Chief Executive Officer (CEO) of CENTOGENE.

Effective June 1, 2014, Michael handed over the CEO position to founder Arndt Rolfs. As member of the Supervisory Board and one of the main major shareholders, Michael will continue his support for CENTOGENE with his network and strategic understanding.